GW Pharmaceuticals, the British maker of epileptic seizure-control medication Epidiolex, said it was not aware of any supply issues related to the cannabis-derived drug after a tweet from a patient’s father complained he could not source the medicine.
The stock declined further early Thursday before trimming some of the losses mid-morning.
Company spokesman Steve Schultz said there were no supply issues relating to Epidiolex but did admit to some issues with insurance companies, according to a report Wednesday by New Cannabis Ventures.
Flinn tweeted Thursday that his daughter’s Epidiolex had arrived “after 19 calls + 338 min on phone. Still not clear on hold up.”
United Kingdom-based GW trades on the Nasdaq under the ticker GWPH.